

Phospho-ATF2 (Thr71) Polyclonal Antibody

Product Details	
Size	100 µL
Species Reactivity	Human
Host/Isotype	Rabbit / IgG
Class	Polyclonal
Type	Antibody
Conjugate	Unconjugated
Immunogen	Chemically synthesized phosphopeptide derived from a region of human ATF2 that contains threonine 71
Form	Liquid
Purification	Antigen affinity chromatography
Storage buffer	Dulbecco's PBS, pH 7.3, with 1mg/mL BSA
Contains	0.05% sodium azide
Storage conditions	-20°C
RRID	AB_2533624

Applications	Tested Dilution	Publications
Western Blot (WB)	1:1,000	-
Immunohistochemistry (Paraffin) (IHC (P))	1:20	-


Product Specific Information

This antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non phosphorylated ATF2. The final product is generated by affinity chromatography using an ATF2-derived peptide phosphorylated at threonine 71. The peptide sequence is conserved in mouse, rat, chicken and frog. Suggested Western blot positive controls: NIH3T3 + anisomycin, or Jurkat + 10 µg/mL anisomycin for 60 minutes.

Product Images For Phospho-ATF2 (Thr71) Polyclonal Antibody


Phospho-ATF2 (Thr71) Antibody (44-295G)


Altered expression of proteins upon cell treatment demonstrates antibody specificity. Western blot using Phospho-ATF2 (Thr71) Polyclonal Antibody (Product # 44-295G), shows increased levels of phospho-ATF2 (Thr71) in U-87MG and K562 cell lines upon Anisomycin treatment. {TM}



Phospho-ATF2 (Thr71) Antibody (44-295G) in WB

Western blot analysis was performed on whole cell extracts (30 µg lysate) of U-87 MG (Lane 1), U-87 MG treated with 25 µg/mL anisomycin for 30 minutes (Lane 2), K562 (Lane 3), K562 treated with 25 µg/mL anisomycin for 30 minutes (Lane 4). The blots were probed with Anti-Phospho-ATF-2 pThr71 Rabbit Polyclonal Antibody (Product # 44-295G, 1-2 µg/mL) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP conjugate (Product # G-21234, 1:5000 dilution). A ~ 54 kDa band corresponding to Phospho-ATF-2 pThr71 was observed across cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).





Phospho-ATF2 (Thr71) Antibody (44-295G) in WB

Extracts of Jurkat cells treated with 10 µg/mL anisomycin for 60 minutes were resolved by SDS-PAGE on a 4-12% Bis-Tris gel and transferred to PVDF. The membrane was blocked with a 5% BSA-TBST buffer for one hour at room temperature and either left untreated (1-4) or treated with lambda () phosphatase (5), then incubated with the ATF2 (pT71) antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 5), the phosphopeptide immunogen (2), the non-phosphopeptide corresponding to the phosphopeptide immunogen (3), or a generic phosphothreonine-containing peptide (4). After washing, the membrane was incubated with goat F (ab')₂ anti rabbit IgG alkaline phosphatase (Product # ALI4405) and signals were detected using the Pierce SuperSignal™ method. The data show that only the phosphopeptide corresponding to ATF2 (pT71) blocks the antibody signal, demonstrating the specificity of the antibody. The data also show that phosphatase stripping eliminates the signal, further verifying that the antibody is phospho-specific.

[View more figures on thermofisher.com](#)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (i) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (ii) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (iii) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (iv) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.